Contineum Therapeutics’ (CTNM) “Overweight” Rating Reiterated at Morgan Stanley

Morgan Stanley restated their overweight rating on shares of Contineum Therapeutics (NASDAQ:CTNM) in a report issued on Friday morning,Benzinga reports. They currently have a $25.00 price objective on the stock.

CTNM has been the topic of several other reports. Robert W. Baird cut their price target on shares of Contineum Therapeutics from $32.00 to $16.00 and set an “outperform” rating on the stock in a report on Friday. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $31.00 price target on shares of Contineum Therapeutics in a report on Thursday, January 9th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $25.25.

Contineum Therapeutics Trading Up 5.1 %

NASDAQ CTNM opened at $6.77 on Friday. The firm’s fifty day simple moving average is $10.12 and its two-hundred day simple moving average is $14.38. Contineum Therapeutics has a 12-month low of $5.92 and a 12-month high of $22.00. The firm has a market capitalization of $174.52 million and a P/E ratio of -1.38.

Institutional Investors Weigh In On Contineum Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in CTNM. Legal & General Group Plc lifted its stake in shares of Contineum Therapeutics by 74.0% during the fourth quarter. Legal & General Group Plc now owns 3,631 shares of the company’s stock worth $53,000 after buying an additional 1,544 shares during the period. Corebridge Financial Inc. lifted its position in Contineum Therapeutics by 73.1% during the fourth quarter. Corebridge Financial Inc. now owns 5,215 shares of the company’s stock valued at $76,000 after purchasing an additional 2,202 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Contineum Therapeutics by 90.4% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,860 shares of the company’s stock valued at $86,000 after purchasing an additional 2,783 shares during the period. MetLife Investment Management LLC acquired a new position in Contineum Therapeutics during the fourth quarter valued at $103,000. Finally, Rhumbline Advisers lifted its position in Contineum Therapeutics by 36.3% during the fourth quarter. Rhumbline Advisers now owns 8,233 shares of the company’s stock valued at $121,000 after purchasing an additional 2,191 shares during the period.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).